MedTrace Logo

Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes

NCT01467401 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 292

Last updated 2017-02-24

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart (NovoMix®30) to that of biphasic human insulin (Mixtard® 30) in subjects with type 2 diabetes.

Conditions

Interventions

DRUG

biphasic insulin aspart

Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily

DRUG

biphasic human insulin

Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-19
Primary Completion
2003-05-15
Completion
2003-05-15

Countries

  • Denmark
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01467401 on ClinicalTrials.gov